Literature DB >> 27379553

Eliminating Xenoantigen Expression on Swine RBC.

Zheng-Yu Wang1, Gregory R Martens, Ross L Blankenship, Richard A Sidner, Ping Li, Jose L Estrada, Matthew Tector, A Joseph Tector.   

Abstract

BACKGROUND: The rapidly improving tools of genetic engineering may make it possible to overcome the humoral immune barrier that prevents xenotransplantation. We hypothesize that levels of human antibody binding to donor tissues from swine must approximate the antibody binding occurring in allotransplantation. It is uncertain if this is an attainable goal. Here we perform an initial analysis of this issue by comparing human antibody binding to red blood cells (RBC) isolated from knockout swine and to allogeneic or autologous human RBC.
METHODS: Human sera were incubated with RBC isolated from various genetically engineered swine or from humans. The level of IgG and IgM binding to these cells were compared using either flow cytometry or a novel mass spectrometric assay.
RESULTS: Mass spectroscopic quantitation of human antibody binding demonstrated that as few as 3 gene inactivations can reduce the levels human antibody binding to swine RBC that is as low as autologous human RBC. Flow cytometry showed that RBC from 2-gene knockout swine exhibited less human antibody binding than human blood group O allogeneic RBC in 22% of tested sera. Deletion of a third gene from pigs resulted in 30% of human samples having less IgG and IgM RBC xenoreactivity than alloreactivity.
CONCLUSIONS: Xenoantigenicity of swine RBC can be eliminated via gene disruption. These results suggest that the gene knockout approach may be able reduce antigenicity in other pig tissues to levels that enable the xenotransplantation humoral barrier to be overcome.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27379553     DOI: 10.1097/TP.0000000000001302

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

2.  Carbohydrate antigen expression and anti-pig antibodies in New World capuchin monkeys: Relevance to studies of xenotransplantation.

Authors:  Qi Li; Sahar Shaikh; Hayato Iwase; Cassandra Long; Whayoung Lee; Zhongqiang Zhang; Yi Wang; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Xenotransplantation       Date:  2019-02-16       Impact factor: 3.907

3.  The impact of serum incubation time on IgM/IgG binding to porcine aortic endothelial cells.

Authors:  Zhongqiang Zhang; Bingsi Gao; Chengjiang Zhao; Cassandra Long; Haizhi Qi; Mohamed Ezzelarab; David Kc Cooper; Hidetaka Hara
Journal:  Xenotransplantation       Date:  2017-05-25       Impact factor: 3.907

4.  Initial experimental experience of triple-knockout pig red blood cells as potential sources for transfusion in alloimmunized patients with sickle cell disease.

Authors:  Takayuki Yamamoto; Mohamed H Bikhet; Marisa B Marques; Huy Q Nguyen; Yehua Cui; Mariyam Javed; Syed Sikandar Raza; David Ayares; Hayato Iwase; David K C Cooper; Hidetaka Hara
Journal:  Transfusion       Date:  2021-09-22       Impact factor: 3.157

5.  Antigenicity of tissues and organs from GGTA1/CMAH/β4GalNT2 triple gene knockout pigs.

Authors:  Rong-Gen Wang; Miaomiao Ruan; Run-Jie Zhang; Lei Chen; Xiao-Xue Li; Bin Fang; Chu Li; Xue-Yang Ren; Ji-Ying Liu; Qiang Xiong; Li-Ning Zhang; Yong Jin; Lin Li; Rongfeng Li; Ying Wang; Hai-Yuan Yang; Yi-Fan Dai
Journal:  J Biomed Res       Date:  2018-07-11

6.  N-glycolylneuraminic acid knockout reduces erythrocyte sequestration and thromboxane elaboration in an ex vivo pig-to-human xenoperfusion model.

Authors:  Arielle Cimeno; Wessam Hassanein; Beth M French; Jessica M Powell; Lars Burdorf; Olga Goloubeva; Xiangfei Cheng; Dawn M Parsell; Jagdeece Ramsoondar; Kasinath Kuravi; Todd Vaught; Mehmet C Uluer; Emily Redding; Natalie O'Neill; Christopher Laird; Alena Hershfeld; Ivan Tatarov; Kathryn Thomas; David Ayares; Agnes M Azimzadeh; Richard N Pierson; Rolf N Barth; John C LaMattina
Journal:  Xenotransplantation       Date:  2017-09-22       Impact factor: 3.907

Review 7.  Does human leukocyte antigens sensitization matter for xenotransplantation?

Authors:  Guerard W Byrne
Journal:  Xenotransplantation       Date:  2018-05       Impact factor: 3.907

8.  Anti-Neu5Gc and anti-non-Neu5Gc antibodies in healthy humans.

Authors:  Bingsi Gao; Cassandra Long; Whayoung Lee; Zhongqiang Zhang; Xiaotian Gao; Doug Landsittel; Mohamed Ezzelarab; David Ayares; Yuliang Huang; David K C Cooper; Yi Wang; Hidetaka Hara
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

9.  Effect of intravenous immunoglobulin (IVIg) on primate complement-dependent cytotoxicity of genetically engineered pig cells: relevance to clinical xenotransplantation.

Authors:  Takayuki Yamamoto; Yehua Cui; Diyan Patel; Abhijit Jagdale; Hayato Iwase; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

Review 10.  B4GALNT2 and xenotransplantation: A newly appreciated xenogeneic antigen.

Authors:  Guerard Byrne; Saadullah Ahmad-Villiers; Zeji Du; Christopher McGregor
Journal:  Xenotransplantation       Date:  2018-03-31       Impact factor: 3.907

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.